RADIATION THERAPY ONCOLOGY GROUP (RTOG)--HEADQUARTERS

肿瘤放射治疗组 (RTOG)——总部

• 批准号: 2086964
• 负责人: WALTER J CURRAN
• 金额: $ 404.15万
• 依托单位: AMERICAN COLLEGE OF RADIOLOGY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-02-01 至 1996-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2086964
• 关键词: alpha fetoprotein; bladder neoplasm; brain neoplasms; bromodeoxyuridine; central nervous system neoplasms; cervix neoplasms; chemoprevention; cis platinum compound; clinical trials; colon neoplasms; combination cancer therapy; computer assisted diagnosis; cooperative study; doxorubicin; drug adverse effect; etoposide; flow cytometry; fluorouracil; glioma; head /neck neoplasm; hepatocellular carcinoma; hormone therapy; human morbidity; human subject; human therapy evaluation; hypoxia; idoxuridine; immunocytochemistry; ionizing radiation; larynx neoplasms; linear energy transfer; lung neoplasms; lymphoma; metastasis; mitomycin C; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer radionuclide therapy; neoplasm /cancer surgery; neoplasm /cancer thermotherapy; pharynx neoplasms; prednisone; prognosis; prostate neoplasms; quality of life; radiation sensitivity; radiation therapy dosage; radioprotective agents; radiosensitizer; rectum neoplasms

Radiation Therapy Oncology Group (RTOG), a cooperative association of physicians (radiation, medical and surgical oncologists, pathologists), laboratory scientists (tumor biologists, physicists), and biostatisticians, has been honed to a sharp instrument for clinical trials in cancer treatment in the 2.5 years since its last renewal application. It has recruited new institutions and new leaders. It has sharply reduced accrual to Phase I/II studies emphasizing Phase III trials seeking improved survival. Phase III trials have been, or will soon be completed with inoperable carcinoma of the esophagus, lung, and bladder. Significant improvements in survival in cancer of the cervix and inoperable cancer of the esophagus have been reported. In each of the disease sites studied by RTOG (brain, head & neck, GI, GU, lung) local-regional tumor control is a major issue. New studies confirming the importance of local-regional control in preventing metastasis and increasing survival have led to new strategies to increase total doses with radiation therapy to combine surgical resection with chemotherapy and radiation therapy, and to use chemotherapy and hormone therapy as adjuncts to local-regional treatments while simultaneously attacking distant micrometastasis. Decrease in morbidity by preservation of organ structure and function is second only to improve survival as an aim; studies are underway or planned to spare the bladder, anal canal, distal rectum, and larynx. Assessment of outcomes for minorities in RTOG studies and the addition of the female genital tract as a site are strong moves to address issues for Special Populations. 3D- Conformal Radiation Therapy was added as a new treatment modality joining time/dose, chemical & biological modifiers, intraoperative radiation therapy, systemic radionuclides. Research planning for hyperthermia was discontinued. Exacting quality assurance guidelines are pursued for both standard and new modalities. Chemoprevention of second malignancies tumors based on models derived from RTOG data bases is now a major thrust led by the Medical Oncology Committee. Laboratory studies (cellular and molecular indices of proliferation, assays of inherent radiosensitivity, cell hypoxic fraction) are underway and planned by the Pathology and Tumor Biology Committees to better understand outcomes of specific treatments, and to select patients for more effective therapies in the future. Quality of life studies and late effects assessments, under new committees, complement the emphasis on improving survival and organ preservation. The large data bases and long-term observations available from RTOG studies continue to serve as unique resources to study-specific disease sites. Finally, the marked increase in accrual, after a period of uncertainty with the new reimbursement approach, assures that clinical investigations by RTOG will be completed quickly and that the new results will rapidly be available for planning future studies of cancer treatment.

放射疗法肿瘤学组（RTOG），合作社 医师（辐射，医学和外科肿瘤学家，病理学家）， 实验室科学家（肿瘤生物学家，物理学家）和生物统计学家， 已经磨练了一种用于癌症临床试验的尖锐仪器 自上次续签应用以来的2。5年中的治疗。 它有 招募了新机构和新领导人。 它大大降低了应计 第I/II期研究强调寻求改进的III期试验 生存。 第三阶段试验已经或很快就会完成 食管，肺和膀胱的无法手术癌。 重要的 子宫颈癌和无法手术的癌症的生存改善 食管已有报道。 在每个疾病部位 RTOG（大脑，头部和颈部，GI，GU，肺）局部区域肿瘤控制是一个 主要问题。 新研究证实了地方区域的重要性 防止转移和增加生存的控制导致了新的 通过放射治疗增加总剂量的策略 通过化学疗法和放射疗法的手术切除，并使用 化学疗法和激素疗法作为局部区域疗法的辅助治疗 同时攻击遥远的微晶。 减少 通过保存器官结构和功能的发病率仅次于 改善生存作为目标；研究正在进行或计划节省 膀胱，肛管，远端直肠和喉。 评估结果 RTOG研究中的少数族裔和女性生殖道的添加 网站是解决特殊人群问题的强大动作。 3D- 添加了保形辐射疗法作为一种新的治疗方式加入 时间/剂量，化学和生物修饰符，术中辐射 治疗，全身放射性核素。 热疗研究计划是 停产。 遵守了严格的质量保证准则 标准和新方式。 第二种恶性肿瘤的化学预防 基于从RTOG数据库中得出的模型，现在是由 医学肿瘤学委员会。 实验室研究（细胞和分子 增殖指标，固有放射敏性的测定，细胞低氧 分数正在进行中，并计划于病理和肿瘤生物学 更好地了解特定治疗结果的委员会 将来选择患者进行更有效的疗法。 质量 生命研究和迟到效应评估，在新委员会下，补充 强调改善生存和器官保存。 大数据 RTOG研究可提供的基础和长期观察继续 作为研究特定疾病部位的独特资源。 最后， 在新的不确定性之后，应计的显着增加 报销方法，确保RTOG的临床研究将 快速完成，新结果将迅速可用于 计划未来的癌症治疗研究。